Insider Purchases: Inside the Buy
Tag: undervalued stocks
👁️ CooperCompanies (COO): Insiders Buy $1.33M at $53–$54 as the Stock Crashes
Three CooperCompanies directors just put $1.33 million of their own money into COO near $53–$54. Add record $273M free cash flow, an expanded $3B buyback authorization and an 11.1× forward P/E—and this beaten-down medtech stock deserves a much closer look. 👁️
🦴 Enovis (ENOV): CEO Buys the $19 Crash—Is This Falling Knife Finally a Buy? 🤖
Enovis CEO Damien McDonald bought ENOV again after shares collapsed toward $19. Insiders are accumulating, institutions remain heavily invested, analysts see substantial upside and adjusted valuation has fallen below 5x forward earnings. But short interest is high, leverage and integration risks remain—and momentum is dreadful. ENOV may be the ultimate FunStock signal collision.
👟 DICK’S Sporting Goods (DKS): Insiders Buy $2.9M After a 30% Crash
DICK’S Sporting Goods plunged roughly 30% as Foot Locker weakness rattled Wall Street. Then three directors bought $2.94 million. With core DICK’S comps up 4.9%, operating cash flow at $792 million and the stock at 9.3x forward earnings, is Wall Street pricing temporary integration pain like permanent deterioration?
CEO Bets $11.9M: Is Oscar Health (OSCR) About to Shock the Market? 🚀
Oscar Health (OSCR) is no longer just a flashy disruptor—it’s aiming for profitability. With CEO Mark Bertolini buying $11.9M in stock and revenue projected to hit $19B in 2026, this could be one of the most compelling turnaround plays in healthcare.
Phreesia (PHR): Profitable… Then Crushed — Why Insiders Are Loading Up
Phreesia just hit profitability—and got punished for it. With insiders loading up and institutions fully committed, is this a classic overreaction or a value trap? Let’s decode the dip.
CPRI Stock Analysis 2026: Is Capri Holdings a Post-Versace Value Gem or a Fashion Victim?
Capri Holdings sold Versace, cleaned up its balance sheet, and now trades near multi-year lows. With insider buying and heavy institutional ownership, investors face a classic question: is CPRI a luxury turnaround or a fading fashion house?
Fiserv: Can Its Clover Come with Four Leaves Or Is It Just Three for Faith, Hope, and Love?
Insiders are buying, institutions are loading up, shorts are barely awake, and Fiserv now trades at deep-value multiples. With Clover, cash flow, and a credible turnaround plan, is this three-leaf fintech about to sprout a fourth? 🍀
Arrow Electronics: A Straight Arrow, But the CEO Sees a Bullet
Arrow Electronics CEO Sean Kerins just bought nearly $1M of ARW stock. Is this undervalued tech distributor about to rebound, or just cruising under the radar? We take a shot at the bullseye—with puns and charts.
Does Align Technology’s Recovery Plan Have Teeth? The CEO Thinks So.
Align Technology insiders are smiling—because they’re buying. With a CEO purchase nearing $1M and Wall Street holding more shares than exist, ALGN may be regaining its shine. But should you sink your teeth into it now?
🥞 Pra Group: No Fun to Get Their Call But Fun to Call Their Stock!
They buy bad debt for pennies, chase it like bounty hunters, and sometimes spin a tidy profit from society’s financial skeletons. But is PRA Group (PRAA) a hidden gem—or a value trap in disguise? We dig deep into this curious case.